Neogenomics Inc (NASDAQ: NEO) on Friday, plunged -4.75% from the previous trading day, before settling in for the closing price of $15.79. Within the past 52 weeks, NEO’s price has moved between $12.77 and $21.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 17.35%. The company achieved an average annual earnings per share of 180.95%. With a float of $126.77 million, this company’s outstanding shares have now reached $127.37 million.
The extent of productivity of a business whose workforce counts for 2100 workers is very important to gauge. In terms of profitability, gross margin is 42.47%, operating margin of -13.71%, and the pretax margin is -12.39%.
Neogenomics Inc (NEO) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Neogenomics Inc is 1.24%, while institutional ownership is 97.47%. The most recent insider transaction that took place on Nov 15 ’24, was worth 81,713. Before that another transaction happened on Aug 15 ’24, when Company’s General Counsel sold 1,040 for $16.05, making the entire transaction worth $16,695. This insider now owns 43,813 shares in total.
Neogenomics Inc (NEO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 180.95% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Neogenomics Inc (NEO) is currently performing well based on its current performance indicators. A quick ratio of 1.91 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.20 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
The latest stats from [Neogenomics Inc, NEO] show that its last 5-days average volume of 0.72 million was inferior to 0.82 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 74.33%. Additionally, its Average True Range was 0.63.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 41.20%, which indicates a significant decrease from 54.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.55% in the past 14 days, which was lower than the 50.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.67, while its 200-day Moving Average is $14.86. Now, the first resistance to watch is $15.70. This is followed by the second major resistance level at $16.37. The third major resistance level sits at $16.71. If the price goes on to break the first support level at $14.69, it is likely to go to the next support level at $14.35. Assuming the price breaks the second support level, the third support level stands at $13.68.
Neogenomics Inc (NASDAQ: NEO) Key Stats
Market capitalization of the company is 1.84 billion based on 128,361K outstanding shares. Right now, sales total 591,640 K and income totals -87,970 K. The company made 167,820 K in profit during its latest quarter, and -17,700 K in sales during its previous quarter.
